New KRAS Drug Shows Real Promise Against Deadly Pancreatic Cancer
A once-undruggable cancer target may finally be cracked, with new data on daraxonrasib offering hope for pancreatic cancer patients.
Summary
For decades, a protein called KRAS — mutated in many of the deadliest cancers — was considered impossible to target with drugs. Now, Revolution Medicines has released promising results for daraxonrasib in pancreatic cancer, one of the hardest-to-treat cancers known. This breakthrough is the result of years of research and may signal the beginning of a new wave of RAS-targeting therapies. Separately, Novo Nordisk reported positive Phase 3 results for an oral sickle cell drug, and Eli Lilly is reportedly acquiring an in-vivo CAR-T therapy developer for over $2 billion. Together, these developments reflect a rapidly advancing landscape in targeted cancer and genetic disease treatment.
Detailed Summary
For decades, the KRAS protein stood as one of oncology's most frustrating dead ends. Mutated in a large proportion of pancreatic, lung, and colorectal cancers, KRAS was long labeled 'undruggable' because its smooth surface offered no obvious place for a drug molecule to bind. That label may now be obsolete.
Revolution Medicines recently released clinical results for daraxonrasib in pancreatic cancer patients — a disease with a five-year survival rate below 15% and few effective treatment options. The data suggest meaningful clinical activity, offering a rare signal of hope in a historically intractable cancer type. Researchers describe this as potentially the opening of a broader wave of RAS inhibitor therapies.
The significance extends beyond one drug. KRAS mutations drive tumor growth across multiple cancer types, meaning a validated drugging strategy could eventually benefit millions of patients. The path here required years of structural biology innovation, including identifying previously unknown binding pockets on the KRAS protein surface.
Also in this news roundup: Novo Nordisk announced its oral drug etavopivat met Phase 3 goals in sickle cell disease, reducing painful crises and improving hemoglobin response — a meaningful advance for a condition with limited oral treatment options. Eli Lilly is reportedly close to a $2 billion-plus acquisition of Kelonia Therapeutics, which develops in-vivo CAR-T therapies that engineer cancer-killing immune cells directly inside the body.
Caveats apply throughout. The KRAS daraxonrasib data were released via press coverage of early results, not yet a peer-reviewed publication. Pancreatic cancer trials have disappointed before, and longer follow-up data will be essential. Still, the convergence of KRAS druggability, next-generation cell therapies, and oral treatments for genetic diseases marks a genuinely significant moment in translational medicine.
Key Findings
- Daraxonrasib showed clinical activity against pancreatic cancer, targeting the long-'undruggable' KRAS mutation.
- KRAS mutations drive multiple deadly cancers; cracking this target could benefit millions of patients globally.
- Novo Nordisk's oral drug etavopivat met Phase 3 goals in sickle cell disease, reducing pain crises.
- Eli Lilly is reportedly acquiring in-vivo CAR-T developer Kelonia Therapeutics for over $2 billion.
- A new wave of RAS inhibitor drugs may be emerging, following years of structural biology breakthroughs.
Methodology
This is a news digest from STAT News, a credible specialist biotech and health journalism outlet. The KRAS section is a summary of a paywalled feature article; primary clinical data are not directly quoted or peer-reviewed in this excerpt. Supporting items reference Phase 3 trial announcements and Wall Street Journal reporting.
Study Limitations
The full daraxonrasib data are behind a paywall and have not been peer-reviewed based on available content. Clinical benefit in pancreatic cancer must be confirmed with longer follow-up and published trial data. This article is a news summary, not a primary research source.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.